The Effect of Platelet-Rich Plasma on Endothelial Progenitor Cell Functionality
Sofia Sidiropoulou1, Styliani Papadaki1, Aikaterini N Tsouka1
1Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, School of Sciences, University of Ioannina, Ioannina, Greece.
Angiology
|March 8, 2021
Summary
Platelet-rich plasma (PRP) activates endothelial progenitor cells (EPCs) for vascular repair. However, aggregated platelets lose this ability, but ticagrelor restores PRP
Area of Science:
- Cardiovascular Biology
- Endothelial Cell Biology
- Platelet Function
Background:
- Platelets are crucial for vascular repair by mediating endothelial progenitor cell (EPC) recruitment and maturation.
- The precise mechanisms by which platelets influence EPC function remain incompletely understood.
- Investigating platelet-rich plasma (PRP) effects on endothelial cells is key to understanding vascular regeneration.
Purpose of the Study:
- To investigate the impact of platelet-rich plasma (PRP) on the functional activation of CD34+-derived late-outgrowth endothelial cells (OECs).
- To elucidate the role of platelet aggregation in modulating PRP's effect on OEC activation.
- To assess the potential of platelet inhibition to enhance PRP-mediated endothelial cell activation.
Main Methods:
- Coincubation of OECs with PRP under conditions of platelet aggregation (induced by ADP) and nonaggregation.
- Evaluation of OEC activation markers: prostacyclin (PGI2) and monocyte chemoattractant protein-1 (MCP-1) release, and intercellular adhesion molecule-1 (ICAM-1) expression.
- Assessment of the effects of ticagrelor, a P2Y12 antagonist, on PRP-induced OEC activation, with similar experiments conducted on human umbilical vein endothelial cells (HUVECs).
Main Results:
- PRP significantly increased ICAM-1 expression and PGI2 and MCP-1 secretion from OECs compared to platelet-poor plasma.
- ADP-aggregated platelets within PRP did not induce OEC activation.
- Pretreatment of PRP with ticagrelor prior to ADP activation restored the ability of PRP to significantly increase all measured OEC activation markers.
Conclusions:
- PRP effectively induces OEC activation, a process inhibited by platelet aggregation.
- Platelet inhibition with ticagrelor restores the capacity of PRP to activate OECs.
- Agents like ticagrelor that inhibit platelet aggregation may enhance platelet-EPC interactions, promoting endothelial regeneration and angiogenesis.
Related Concept Videos
01:22Formation of the Platelet Plug
8.0K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.0K
01:18Structure and Function of Platelets
2.4K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.4K